U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H18N2O3.C4H4O4
Molecular Weight 426.4193
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of APLINDORE FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.O=C1CC2=C(N1)C=CC3=C2O[C@@H](CNCC4=CC=CC=C4)CO3

InChI

InChIKey=GELJVTSEGKGLDF-QDSMGTAFSA-N
InChI=1S/C18H18N2O3.C4H4O4/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12;5-3(6)1-2-4(7)8/h1-7,13,19H,8-11H2,(H,20,21);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C18H18N2O3
Molecular Weight 310.3471
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Aplindore (DAB-452) is a small molecule that displays potent dopamine D2 receptor partial agonist activity in in vitro and in vivo assays and is predicted to have antipsychotic efficacy without motor side effects. Aplindore had been in phase II clinical trials for the treatment of Parkinson's disease and restless legs syndrome. Aplindore was generally well tolerated and there were no withdrawals due to adverse events and no serious adverse events.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
9.1 null [pKi]
8.54 null [pKi]
7.21 null [pKi]
7.64 null [pKi]
4.87 null [pKi]
6.83 null [pKi]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
1, 3, and 6 mg twice daily
Route of Administration: Oral
In Vitro Use Guide
CHO-D2S-Gαq/o cells were challenged with various doses (up to 10 uM) of aplindore, aripiprazole and quinpirole in the absence and presence of quinpirole (10 nM). Aplindore (at 10 uM, Emax= 56 ± 1%, in the absence and 58 ± 2% in the presence of quinpirole) showed less antagonist activity than aripiprazole (at 10 uM, Emax= 33 ± 6% and 50 ± 2%, respectively) on quinpirole-mediated [Ca2+]i response.
Substance Class Chemical
Record UNII
P13TV5A758
Record Status Validated (UNII)
Record Version